Interaction between doxorubicin and the resistance modifier stilbene on multidrug resistant mouse lymphoma and human breast cancer cells

被引:0
|
作者
Ferreira, Maria-Jose U.
Duarte, Noelia
Gyemant, Nora
Radics, Rita
Cherepnev, Georgy
Varga, Andras
Molnar, Joseph
机构
[1] Univ Lisbon, CECF, Fac Pharm, P-1699 Lisbon, Portugal
[2] Univ Szeged, Dept Med Microbiol, Szeged, Hungary
[3] Humboldt Univ, Dept Med Immunol Charite, Berlin, Germany
[4] Humboldt Univ, Dept Mol Parasitol, Berlin, Germany
关键词
stilbenes; Euphorbia lagascae; multidrug resistance; apoptosis; CHANNEL BLOCKERS; PICEATANNOL; RESVERATROL; AGENTS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The hydroxystilbene trans-3,5,3,4-tetrahydroxystilbene (piceatannol) (1), isolated from the methanol extract of Euphorbia lagascae defatted seeds, was methylated to yield the derivatives trans-3,5,3,4'-tetramethoxystilbene (2), (trans-3,5-dihydroxy-3', 4'-dimethoxystilbene) (3) and trans-3,5,3'-trihydroxy4'-methoxystilbene (4). The structures of the compounds were assigned by spectroscopic methods (IR, H-1-NMR, C-13-NMR and MS). The ability of piceatannol (1) and the three methylated derivatives to modulate the transport activity of P-glycoprotein (P-gp) and apoptosis induction on the L5178 mouse lymphoma cell line containing the human MDR1 gene was studied by flow cytometry. The reversal of multidrug-resistance (MDR) was investigated by measuring the accumulation of rhodamine-123, a fluorescent substrate analog of doxorubicin, in cancer cells. Verapamil was applied as a positive control. For the evaluation of the compounds as apoptosis inducers, tumor cells were stained with FITC-labelled annexin-V and propidium iodide. The tetramethylated derivative (2) was found to be a powerful inhibitor of P-gp activity. Compounds I and 2 showed an increased apoptotic effect in the MDR subline, the most active being piceatannol (1). Furthermore, in the combination chemotherapy model, the interaction between doxorubicin and the resistance modifier 2 was studied in vitro. The results of checkerboard experiments indicated that the type of interaction was additive between doxorubicin and compound 2 on the human MDR1 gene-transfected mouse lymphoma cells. However, in the MCF7/dox human breast cancer cells, the interaction was non-additive. The degree of additive and non-additive interactions were close to the borderline of the FIX values corresponding to the two types of interactions.
引用
收藏
页码:3541 / 3546
页数:6
相关论文
共 50 条
  • [41] Germacrone reverses Adriamycin resistance through cell apoptosis in multidrug-resistant breast cancer cells
    Xie, Xiao-Hong
    Zhao, Hong
    Hu, Yuan-Yuan
    Gu, Xi-Dong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2014, 8 (05) : 1611 - 1615
  • [42] Reversion of Multidrug Resistance in a Chemoresistant Human Breast Cancer Cell Line by β-Elemene
    Xu, Hong-Bin
    Li, Ling
    Fu, Jun
    Mao, Xia-Ping
    Xu, Lu-Zhong
    PHARMACOLOGY, 2012, 89 (5-6) : 303 - 312
  • [43] Effects of Ganoderic acid Me on inhibiting multidrug resistance and inducing apoptosis in multidrug resistant colon cancer cells
    Jiang, Zijing
    Jin, Tiantian
    Gao, Feng
    Liu, Jianwen
    Zhong, Jianjiang
    Zhao, Heng
    PROCESS BIOCHEMISTRY, 2011, 46 (06) : 1307 - 1314
  • [44] Conserved cell populations in doxorubicin-resistant human nasal natural killer/T cell lymphoma cell line: super multidrug resistant cells?
    Zhang, Xudong
    Fu, Xiaorui
    Dong, Meng
    Yang, Zhenzhen
    Wu, Shaoxuan
    Ma, Mijing
    Li, Zhaoming
    Wang, Xinhua
    Li, Ling
    Li, Xin
    Sun, Zhenchang
    Chang, Yu
    Nan, Feifei
    Yan, Jiaqin
    Mao, Yun
    Zhang, Mingzhi
    Chen, Qingjiang
    CANCER CELL INTERNATIONAL, 2018, 18
  • [45] A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells
    Shuhendler, Adam J.
    Cheung, Richard Y.
    Manias, Janet
    Connor, Allegra
    Rauth, Andrew M.
    Wu, Xiao Yu
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (02) : 255 - 269
  • [46] A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells
    Adam J. Shuhendler
    Richard Y. Cheung
    Janet Manias
    Allegra Connor
    Andrew M. Rauth
    Xiao Yu Wu
    Breast Cancer Research and Treatment, 2010, 119 : 255 - 269
  • [47] Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells
    Zhou, Ting
    Duan, Jingjing
    Wang, Yan
    Chen, Xin
    Zhou, Ganping
    Wang, Rongkan
    Fu, Liwu
    Xu, Feng
    TUMOR BIOLOGY, 2012, 33 (05) : 1299 - 1306
  • [48] siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma
    Yang, Haitao
    Ding, Rui
    Tong, Zhong
    Huang, Jun
    Shen, Lei
    Sun, Yu
    Liao, Jing
    Yang, Zhijian
    Hoffman, Robert M.
    Wang, Chenghong
    Meng, Xiangling
    ANTICANCER RESEARCH, 2016, 36 (06) : 2675 - 2682
  • [49] Reversal of P-glycoprotein-mediated multidrug resistance by novel curcumin analogues in paclitaxel-resistant human breast cancer cells
    Gao, Lei
    Zhao, Peiran
    Li, Yang
    Yang, Dawei
    Hu, Ping
    Li, Lianzhi
    Cheng, Yufeng
    Yao, Hengchen
    BIOCHEMISTRY AND CELL BIOLOGY, 2020, 98 (04) : 484 - 491
  • [50] SENSITIZATION OF MULTIDRUG-RESISTANT COLON CANCER-CELLS TO DOXORUBICIN ENCAPSULATED IN LIPOSOMES
    OUDARD, S
    THIERRY, A
    JORGENSEN, TJ
    RAHMAN, A
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1991, 28 (04) : 259 - 265